Home › Funds › Bellevue Group AG › RVMD

Bellevue Group AG position in RVMD

REVOLUTION MEDICINES INC · Health Care

Bellevue Group AG reported holding 1,048,014 shares of RVMD (REVOLUTION MEDICINES INC) in its Q2 2026 13F filing — a position valued at US$196.3M, representing 4.13% of its reported portfolio and ranking #5 among its reported holdings. Bellevue Group AG has disclosed RVMD holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.05M sh
Reported value held$196.27M
Portfolio Weight4.13%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Bellevue Group AG's RVMD position evolved

Bellevue Group AG first disclosed a stake in RVMD in Q3 2023 at 4,721,500 shares (US$130.7M). The position peaked in Q4 2025 at 5,005,719 shares, worth US$398.7M. Across 12 filings, Bellevue Group AG increased the stake 3 time(s), trimmed it 6 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 1,048,014 shares valued at US$196.3M — a reduction of -496,442 shares quarter over quarter.. Notable position changes include a 69% trim in Q1 2026 (shares rose 93% over the following quarter), a 32% trim in Q2 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 4.72M $130.69M New
Q4 2023 5.09M $146.01M Add
Q1 2024 5.07M $163.52M Hold
Q2 2024 5.03M $195.18M Reduce
Q3 2024 4.87M $220.92M Reduce
Q4 2024 4.39M $191.88M Reduce
Q1 2025 4.37M $154.68M Hold
Q2 2025 4.58M $168.47M Add
Q3 2025 5.57M $260.30M Add
Q4 2025 5.01M $398.71M Reduce
Q1 2026 1.54M $150.20M Reduce
Q2 2026 1.05M $196.27M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RVMD and 13F data

RVMD (REVOLUTION MEDICINES INC) is a Health Care company. 60 other funds we track also report a position in RVMD — the largest reported positions include Farallon Capital Management (US$2.54B), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$2.54B), BAKER BROS. ADVISORS LP (US$2.14B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RVMD

All RVMD fund holders →

FAQ

How long has Bellevue Group AG held RVMD?

Bellevue Group AG has disclosed RVMD holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Bellevue Group AG's current position in RVMD?

As of Q2 2026, Bellevue Group AG holds 1.05M shares of RVMD (REVOLUTION MEDICINES INC), valued at $196.27M, representing 4.13% of its reported portfolio and ranking #5.

Has Bellevue Group AG been buying or selling RVMD?

In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in RVMD. The position peaked in Q4 2025 at 5.01M shares.

Which other funds hold RVMD?

Other major institutional holders of RVMD include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., BAKER BROS. ADVISORS LP, among 60 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.